These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30838489)

  • 1. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.
    Liu F; Cox CD; Chowdhury R; Dovek L; Nguyen H; Li T; Li S; Ozer B; Chou A; Nguyen N; Wei B; Antonios J; Soto H; Kornblum H; Liau L; Prins R; Nghiemphu PL; Yong W; Cloughesy T; Lai A
    J Neurooncol; 2019 May; 142(3):423-434. PubMed ID: 30838489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
    Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
    Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.
    Fukushima T; Kawaguchi M; Yamamoto K; Yamashita F; Izumi A; Kaieda T; Takezaki Y; Itoh H; Takeshima H; Kataoka H
    Cancer Sci; 2018 Sep; 109(9):2970-2979. PubMed ID: 29987920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiles of long- and short-term glioblastoma survivors.
    Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
    Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
    Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
    Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of the CpG island methylator phenotype during glioma progression and identification of methylated loci in secondary glioblastomas.
    Hill VK; Shinawi T; Ricketts CJ; Krex D; Schackert G; Bauer J; Wei W; Cruickshank G; Maher ER; Latif F
    BMC Cancer; 2014 Jul; 14():506. PubMed ID: 25012071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
    Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
    Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer.
    Dong W; Chen X; Xie J; Sun P; Wu Y
    Int J Cancer; 2010 Oct; 127(7):1526-34. PubMed ID: 20063316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
    Laffaire J; Everhard S; Idbaih A; Crinière E; Marie Y; de Reyniès A; Schiappa R; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Thillet J; Ducray F
    Neuro Oncol; 2011 Jan; 13(1):84-98. PubMed ID: 20926426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U3 snoRNA-mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild-type glioblastoma cells.
    Dong W; Liu Y; Wang P; Ruan X; Liu L; Xue Y; Ma T; E T; Wang D; Yang C; Lin H; Song J; Liu X
    CNS Neurosci Ther; 2023 Oct; 29(10):2811-2825. PubMed ID: 37066523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.
    Pereira MS; Celeiro SP; Costa ÂM; Pinto F; Popov S; de Almeida GC; Amorim J; Pires MM; Pinheiro C; Lopes JM; Honavar M; Costa P; Pimentel J; Jones C; Reis RM; Viana-Pereira M
    Cell Oncol (Dordr); 2020 Feb; 43(1):107-121. PubMed ID: 31701492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.
    Kongkham PN; Northcott PA; Ra YS; Nakahara Y; Mainprize TG; Croul SE; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2008 Dec; 68(23):9945-53. PubMed ID: 19047176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.